about
Targeting the ubiquitin pathway for cancer treatmentTargeting Cdc20 as a novel cancer therapeutic strategy.Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
P2860
Q26866185-68AE2CFF-36EE-41B4-8249-C1119990F75DQ35688708-6EDF0721-285F-45DE-8A26-1BD2A3146A19Q35969785-5A34CD04-87D9-4A2E-87F1-C8875D470F8FQ37146291-9BB7F4E1-B61B-4B0B-AD71-CFBC052EFDA6Q38989789-891FDE9A-5942-4F81-AEDE-3AF889507FA6Q39903788-A6CA880D-7DA9-4B66-BD0E-590D5DBAB296Q44597478-BF25C300-3576-431E-8ADA-CA87869405B1
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Carfilzomib in multiple myeloma.
@en
type
label
Carfilzomib in multiple myeloma.
@en
prefLabel
Carfilzomib in multiple myeloma.
@en
P2860
P1476
Carfilzomib in multiple myeloma.
@en
P2093
Claudia Andreu-Vieyra
James R Berenson
P2860
P304
P356
10.1517/14712598.2014.953050
P407
P577
2014-08-29T00:00:00Z